Healthcare underdogs: opportunities in overlooked OTC stocks Venture Life, Alliance Pharmaceuticals


# # #
Many healthcare firms have been under the weather this year, as investors have rotated out of tried and tested defensive brands into exciting new weight-loss drug developers Eli Lilly and Company (fwd PE 46x) and Novo Nordisk (30x).
Indeed this frenzy in all things "GLP-1"-related has been painful for those stocks left behind (e.g. Pfizer -47% YTD and Bristol Myers Squibb -28% YTD ). Although as patient investors know - when there’s indiscriminate selling, there’s often opportunity too.
For instance, despite posting "resilient and in line" results this year, the over-the-counter (OTC) healthcare products sector has similarly been discarded. With OTC giants Haleon and Kenvue both falling -3% and -11% respectively, alongside AIM stocks (-8%, £42m mrkcap) and (-25%, £214m mrkcap).
In particular, these latter two smallcaps presently trade on 2024 PERs of <6x, offer 10%-15% cashflow yields and are delivering sales growth of 10% for and 7% at . Sure both are deleveraging their balance sheets (est Dec'23 net debt / EBITDA 1.3x for vs 2.0x ) after completing acquisitions in 2022.
Yet equally this is occurring at a rapid clip, which I suspect could provide a catalyst for a major re-rating in 2024.
How much is everyone’s guess. Cavendish have a 68p/share price target on , with consensus correspondingly sitting at >80p for
Stocking fillers anyone?
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.